| 2025-10-07 |
复牌提示：
2025-10-06 19:50:00 停牌，复牌日期 2025-10-08 00:00:01
|
| 2025-10-07 |
详情>>
内部人交易：
ACKERMANN CHRISTINA等共交易24笔
|
| 2025-08-18 |
股东大会：
将于2025-09-24召开股东大会
会议内容 ▼▲
- 1.A proposal (i) authorizing the Board of Directors of Verona Pharma (the “Verona Board”) to take all actions necessary or appropriate for carrying the Scheme of Arrangement into effect and (ii) making certain amendments to the articles of association of Verona Pharma in order to facilitate the Transaction;
2.A non-binding advisory proposal to approve certain compensation arrangements for Verona Pharma’s named executive officers.
|
| 2025-08-18 |
股东大会：
将于2025-09-24召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the Scheme of Arrangement.
|
| 2025-08-18 |
详情>>
股本变动：
变动后总股本8649.59万股
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益-0.01美元,归母净利润-439.8万美元,同比去年增长95.45%
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益-0.02美元,归母净利润-1631.9万美元,同比去年增长36.73%
|
| 2025-04-29 |
财报披露：
美东时间 2025-04-29 盘前发布财报
|
| 2025-03-18 |
股东大会：
将于2025-04-24召开股东大会
会议内容 ▼▲
- 1.To re-elect, as a Director of the Company, Dr. Kenneth Cunningham, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
2.To re-elect, as a Director of the Company, Mr. Vikas Sinha, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
3.To re-elect, as a Director of the Company, Mr. James Brady, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
4.To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended December 31, 2024 and the report of the auditors thereon (the “2024 U.K. Annual Report”).
5.To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended December 31, 2024, as set out on pages 21 to 43 of the 2024 U.K. Annual Report.
6.To re-appoint Ernst & Young LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
7.To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2025.
8.To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers.
9.To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of 7,031,895 (being up to a maximum of 140,637,892 shares representing 20% of the Company’s existing ordinary share capital as at the close of business on March 11, 2025 (being the latest practicable date prior to publication of this document)) to such persons at such times and upon such conditions as the directors may determine (subject to the Company’s Articles of Association).
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-0.27美元,归母净利润-1.73亿美元,同比去年增长-218.96%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.22美元,归母净利润-1.4亿美元,同比去年增长-246.92%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.15美元,归母净利润-9662.9万美元,同比去年增长-278.2%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-0.04美元,归母净利润-2579.4万美元,同比去年增长-54.06%
|
| 2024-03-20 |
股东大会：
将于2024-04-26召开股东大会
会议内容 ▼▲
- 1.To re-elect, as a Director of the Company, Ms. Lisa Deschamps, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers herself for re-election.
2.To re-elect, as a Director of the Company, Dr. Martin Edwards, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
3.To re-elect, as a Director of the Company, Dr. Sven Anders Ullman, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
4.To re-elect, as a Director of the Company, Ms. Christina Ackermann, who retires in accordance with Article 21.2 of the Company’s Articles of Association and offers herself for re-election.
5.To re-elect, as a Director of the Company, Mr. Michael Austwick, who retires in accordance with Article 21.2 of the Company’s Articles of Association and offers himself for re-election.
6.To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended December 31, 2023 and the report of the auditors thereon (the “2023 U.K. Annual Report”).
7.To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended December 31, 2023, as set out on pages 36 to 57 of the 2023 U.K. Annual Report.
8.To receive and approve the U.K. Directors’ Remuneration Policy, as set out on pages 47 to 57 of the U.K. Annual Report, which, if approved, will take effect upon conclusion of the AGM.
9.To approve an increase in the maximum aggregate level of Non-Executive Director annual remuneration (by way of fee) in accordance with Article 21.4 of the Company’s Articles of Association to ￡750,000 per annum on an ongoing basis.
10.To appoint Ernst & Young LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
11.To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2024.
12.To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers.
13.To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of ￡8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Company’s existing ordinary share capital as at the close of business on March 13, 2024 (being the latest practicable date prior to publication of this document)) to such persons at such times and upon such conditions as the directors may determine (subject to the Company’s Articles of Association).
14.Subject to and conditional upon the passing of resolution 13 above, to authorize the Directors pursuant to Section 570 and 573 of the Companies Act to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 13 above and/or to sell ordinary shares held by the Company as treasury shares for cash, as if Section 561(1) of the Companies Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment of equity securities or sale of treasury shares up to an aggregate nominal amount of ￡8,345,745 (being up to a maximum of 166,914,908 shares representing 25% of the Company’s existing ordinary share capital as at the close of business on March 13, 2024 (being the latest practicable date prior to publication of this document)), shall replace any existing disapplication of Section 561 of the Companies Act to the extent not utilized at the date this resolution is passed and shall expire on June 1, 2025 unless previously renewed, varied or revoked by the Company in general meeting, provided that the Company may, before such expiry, make an offer or agreement which would or might require shares in the Company or rights to be allotted or granted or treasury shares to be sold after this authority expires and that the Directors may allot shares in the Company or grant rights or sell treasury shares pursuant to such an offer or agreement as if the authority conferred by this resolution had not expired.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-0.09美元,归母净利润-5436.9万美元,同比去年增长20.86%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.06美元,归母净利润-4023.7万美元,同比去年增长30.92%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-0.04美元,归母净利润-2555万美元,同比去年增长40.03%
|
| 2023-05-09 |
详情>>
业绩披露：
2023年一季报每股收益-0.03美元,归母净利润-1674.3万美元,同比去年增长32.59%
|
| 2023-03-21 |
股东大会：
将于2023-04-27召开股东大会
会议内容 ▼▲
- 1.To re-elect, as a Director of the Company, Dr. David Ebsworth, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
2.To re-elect, as a Director of the Company, Dr. Mahendra Shah, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
3.To re-elect, as a Director of the Company, Dr. David Zaccardelli, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
4.To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended December 31, 2022 and the report of the auditors thereon (the “2022 U.K. Annual Report”).
5.To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended December 31, 2022, as set out on pages 35 to 54 of the 2022 U.K. Annual Report.
6.To re-appoint PricewaterhouseCoopers LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
7.To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2023.
8.To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers.
9.To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers.
10.To approve the adoption of the Verona Pharma plc Second Amended and Restated 2017 Incentive Award Plan (the “Second A&R Plan”).
11.To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of ￡8,145,745 to such persons at such times and upon such conditions as the directors may determine (subject to the Company’s articles of association).
|
| 2022-03-22 |
股东大会：
将于2022-04-27召开股东大会
会议内容 ▼▲
- 1.To re-elect, as a Director of the Company, Dr. Kenneth Cunningham, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
2.To re-elect, as a Director of the Company, Mr. Rishi Gupta, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
3.To re-elect, as a Director of the Company, Mr. Vikas Sinha, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
4.To re-elect, as a Director of the Company, Mr. James Brady, who retires in accordance with Article 21.2 of the Company’s Articles of Association and offers himself for re-election.
5.To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended December 31, 2021 and the report of the auditors thereon (the “2021 U.K. Annual Report”).
6.To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended December 31, 2021, as set out on pages 27 to 46 of the 2021 U.K. Annual Report.
7.To re-appoint PricewaterhouseCoopers LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
8.To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2022.
9.To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of ￡24,702,912 to such persons at such times and upon such conditions as the directors may determine (subject to the Company’s articles of association).
10.Subject to and conditional upon the passing of resolution 9 above, to authorize the Directors pursuant to Section 570 and 573 of the Companies Act to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 9 above and/or to sell ordinary shares held by the Company as treasury shares for cash, as if Section 561(1) of the Companies Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment of equity securities or sale of treasury shares up to an aggregate nominal amount of ￡24,702,912, shall replace any existing disapplication of Section 561 of the Companies Act to the extent not utilized at the date this resolution is passed and shall expire on June 1, 2023 unless previously renewed, varied or revoked by the Company in general meeting, provided that the Company may, before such expiry, make an offer or agreement which would or might require shares in the Company or rights to be allotted or granted or treasury shares to be sold after this authority expires and that the Directors may allot shares in the Company or grant rights or sell treasury shares pursuant to such an offer or agreement as if the authority conferred by this resolution had not expired.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-19 |
股东大会：
将于2021-04-27召开股东大会
会议内容 ▼▲
- 1.To re-elect, as a Director of the Company, Dr. David Ebsworth, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
2.To re-elect, as a Director of the Company, Dr. Martin Edwards, who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
3.To re-elect, as a Director of the Company, Dr. Sven Anders Ullman (known as “Anders Ullman”), who retires in accordance with Article 26.2 of the Company’s Articles of Association and offers himself for re-election.
4.To re-elect, as a Director of the Company, Lisa Deschamps, who retires in accordance with Article 21.2 of the Company’s Articles of Association and offers herself for re-election.
5.To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended December 31, 2020 and the report of the auditors thereon (the “2020 U.K. Annual Report”).
6.To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended December 31, 2020, as set out on pages 28 to 46 of the 2020 U.K. Annual Report.
7.To receive and approve the U.K. Directors’ Remuneration Policy, as set out on pages 38 to 46 of the 2020 U.K. Annual Report, which, if approved, will take effect upon conclusion of the AGM.
8.To re-appoint PricewaterhouseCoopers LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.
9.To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2021.
10.To authorize the Directors generally and unconditionally for the purposes of Section 551 of the U.K. Companies Act 2006 (the “Companies Act”) to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of ￡24,415,222.30 to such persons at such times and upon such conditions as the directors may determine (subject to the Company’s articles of association).
11.Subject to and conditional upon the passing of resolution 10 above, to authorize the Directors pursuant to Section 570 and 573 of the Companies Act to allot equity securities (as defined in Section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 10 above and/or to sell ordinary shares held by the Company as treasury shares for cash, as if Section 561(1) of the Companies Act did not apply to any such allotment or sale, provided that this power shall be limited to the allotment of equity securities or sale of treasury shares up to an aggregate nominal amount of ￡24,415,222.30, shall replace any existing disapplication of section 561 of the Companies Act to the extent not utilized at the date this resolution is passed and shall expire on June 1, 2022 unless previously renewed, varied or revoked by the Company in general meeting, provided that the Company may, before such expiry, make an offer or agreement which would or might require shares in the Company or rights to be allotted or granted or treasury shares to be sold after this authority expires and that the Directors may allot shares in the Company or grant rights or sell treasury shares pursuant to such an offer or agreement as if the authority conferred by this resolution had not expired.
|
| 2020-11-12 |
股东大会：
将于2020-12-18召开股东大会
会议内容 ▼▲
- 1.That, with effect from the conclusion of the meeting,Atticles of Association produced to the meeting be adopted as the Company's Articles of Association in substitution for, and to the exclusion of, the existing Articles of Association.
|
| 2020-03-30 |
股东大会：
将于2020-04-16召开股东大会
|
| 2019-03-26 |
股东大会：
将于2019-05-07召开股东大会
|
| 2018-03-22 |
股东大会：
将于2018-05-02召开股东大会
会议内容 ▼▲
- Ordinary Resolutions
1.To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2017.
2.To approve the Directors’ Remuneration Policy.
3.To approve the Directors’ Remuneration Report.
4.To re-elect David Raymond Ebsworth as a director of the Company.
5.To re-elect Sven Anders Ullman as a director of the Company.
6.To appoint PricewaterhouseCoopers LLP as auditors.
7.To authorise the directors to determine the auditors remuneration.
8.To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.
Special Resolution
9.To authorise the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006.
|